No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for MBX Biosciences, Inc. Common Stock (MBX) stock was $57.29 as of Oct 6, 2026, 11:24 AM EDT, down 2.13% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +248.7%
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions.
Biotechnology · Carmel, IN
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.83
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.78
vs Estimate
$-0.59
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MBX | $2.73B | $57.29 | -2.13% | +248.66% | N/A | N/A | N/A |
| 2PGEN | $2.72B | $7.64 | -1.27% | +137.17% | +8.79% | -12.26% | vs MBX |
| 3ACHC | $2.71B | $29.16 | +1.00% | +6.34% | -13.91% | -5.09% | vs MBX |
| 4AVAH | $2.69B | $12.37 | -0.04% | +43.09% | +9.75% | N/A | vs MBX |
| 5NEOG | $2.68B | $12.28 | -5.65% | +113.91% | -21.13% | -4.56% | vs MBX |
| 6ATRC | $2.78B | $54.63 | -3.09% | +61.56% | -4.06% | +13.44% | vs MBX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 10 analysts
Average Price Target
$94.30
+64.6% upside
Low
$70.00
Current
$57.29
High
$150.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.91 | $-0.83 | $-0.72 | 5 |
| Quarter ending Dec 2026 | $-1.03 | $-0.95 | $-0.88 | 5 |
| Quarter ending Mar 2027 | $-0.92 | $-0.92 | $-0.92 | 3 |
| Quarter ending Jun 2027 | $-0.96 | $-0.96 | $-0.96 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.72 | $-3.09 | $-2.76 | 7 |
| FY 2027 | $-4.43 | $-4.02 | $-3.64 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
